CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

BridgeBio Pharma Q3 revenue more than doubles on Attruby sales and Bayer milestone

By Reuters News


Overview

  • U.S. biopharma firm's Q3 revenue more than doubled yr/yr, driven by Attruby sales and Bayer milestone

  • Company posted Q3 operating loss as costs rose with commercialization and R&D investments

  • Attruby growth led by more newly diagnosed patients starting treatment, boosting first-line share


Outlook

  • BridgeBio expects U.S. launch of BBP-418 for LGMD2I/R9 upon FDA approval in November 2026

  • Company anticipates U.S. launch of oral infigratinib for achondroplasia after February 2027 FDA decision

  • Encaleret for ADH1 has a May 2027 PDUFA date; U.S. launch expected upon approval


Result Drivers

  • ATTRUBY SALES GROWTH - Co said revenue increase was primarily driven by higher U.S. Attruby net product sales, with growth led by treatment-naïve segment and increased share of new patient starts

  • BAYER MILESTONE - Co recognized a one-time $75 mln sales milestone from Bayer under license agreement, contributing to higher license and services revenue

  • OPERATING COSTS - Higher selling, general and administrative expenses and increased R&D spending contributed to Q3 operating loss, reflecting investment in commercialization and late-stage product development


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.42

Q3 Net Loss

$60.50 mln

Q3 Operating Income

-$11.64 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $108.50, about 53.2% above its October 28 closing price of $70.82


Reuters Recommended Reads

  • Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

  • Oct 29 - Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.